HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD: Mascara Cases Prime Examples Of False Product Demonstration

This article was originally published in The Rose Sheet

Executive Summary

The National Advertising Division has come down on firms for mascara ads promoting certain qualified claims while featuring models wearing lash inserts without proper disclosure. Those instances are product demonstrations, and with physical or digital alterations are rendered false unless disclosure is in the main message of the ad, NAD Director Andrea Levine said at the Annual Conference.

You may also be interested in...



Are Beauty Ads Held To Unique Standards? NARB Ruling Spurs Debate

At the National Advertising Division’s Annual Conference, NAD staffers, FTC officials and attorneys discussed whether beauty ads are regulated differently from advertising in other industries. L’Oreal’s successful appeal of a recent NAD decision regarding the use of lash inserts in Maybelline mascara ads could set a new and questionable precedent, according to NAD Director Andrea Levine.

DermStore Claims For SmartLash Eyelash Enhancer Unsupported – NAD

E-commerce firm acquired by Target in August 2013 lacks sufficient evidence for SmartLash claims including “Up to a 68% increase in the appearance of lash length,” according to the advertising watchdog.

L’Oreal Appeals NAD Ruling On Eyelash Enhancement

A National Advertising Division decision concerning implied and express claims in L’Oreal USA ads for mascara products reinforces the watchdog’s position on artificial enhancements to cosmetic advertising that exaggerate potential product benefits – this time focusing on physical (versus digital) alterations.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel